Deton Develop Innovative Device To Improve Diagnosis Of Lung Diseases

Deton Develop Innovative Device To Improve Diagnosis Of Lung Diseases
The morbidity and mortality related to lung diseases is staggering. Hundreds of millions of people are affected by respiratory conditions, and over 4 million people die each year due to lung diseases. Although studies have revealed fewer deaths related to lower respiratory tract infections than 2 decades ago, too many are still dying, with infants and young children especially susceptible. While medical breakthroughs have led to many improvements, it is still difficult to obtain diagnostic information from patients because it is challenging to efficiently and non-invasively access the lungs for a quality sample.

The California-based startup Deton is determined to pioneer lung diagnostics. They are developing a device called the Cough Collector, enabling a non-invasive collection of cough aerosols. When the patient coughs into the mouthpiece of the device, it collects an aerosol of infectious droplets. Contaminants are separated out, and the remaining droplets are siphoned through a specially designed nozzle that deposit the bacteria onto a tiny collection disc. The disc is easily removed from the Cough Collector into a sealed container for analysis, making diagnosis of lower respiratory infections easy, rapid and reliable.

There are long standing challenges in diagnosing lower respiratory infections. In order to provide an accurate diagnosis, doctors have to collect a sample of phlegm from deep within the patient’s lungs. The samples can be very difficult to obtain, especially from children, and are often contaminated by the time they exit the patient’s mouth. Deton has developed an innovative device that could revolutionize the diagnosis of lower respiratory infections, addressing a large unmet clinical need. The non-invasive method allow doctors to appropriately prescribe targeted antibiotic therapies when necessary and avoid ineffective treatments that can lead to antibiotics resistance. The Cough Collector could lead to faster and more effective treatment, can be used by patients in all age groups, potentially increasing access to care and improving health outcomes for millions of people around the world.

Deton has previously received Phase I SBIR funding from NSF and NIH Advanced Small Business Innovation Research grant to support the development of the cough collector and collect proof of concept data. In 2016, the startup raised $600,000 led by a venture fund based in Shanghai and included angel investor participation. They have also been part of the Consortium for Technology and Innovation inPediatrics (CTIP), a pediatric technology accelerator operated by the Center for Innovation at Children’s Hospital Los Angeles, and in 2017 won the ‘Most Promising Company’ at the Molecular Medicine Tri-ConferenceSwimming with the Sharks” competition in San Francisco.

If you appreciate our work, consider making a contribution